ARTCLINE GmbH, a biotech firm focused on developing innovative immune cell-based therapies for intensive care medicine, has secured $3.4M in new funding. The company's primary project, ARTICE technology, is specifically designed to treat bacterial sepsis, a critical area where new approaches are urgently needed.
With a vision to make its advanced therapy approaches available to physicians and hospitals worldwide, ARTCLINE builds on its team's extensive experience in immunology, sepsis diagnostics, and the successful transfer of medical inventions from university research to industrial application.
